Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer

被引：0
|
作者：
Nguyen, Nicholas D. [1 ]
Yu, Meifang [1 ]
Fujimoto, Tara N. [1 ]
Delahoussaye, Abagail [1 ]
Huang, Yanqing [1 ]
Estrada, Manuel A. [1 ]
Taniguchi, Cullen M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
555
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Watanabe, Kazuo
    Sato, Akihiro
    Aoki, Kazunori
    Ochiai, Atsushi
    Makikawa, Mayu
    Nishidate, Masanobu
    Yamaguchi, Kyoko
    Terao, Kimio
    Sawada, Noriaki
    Fujitomo, Takashi
    Fujii, Etsuko
    Kato, Atsuhiko
    Tsunoda, Hiroyuki
    CANCER SCIENCE, 2023, 114 (10) : 4006 - 4019
  • [42] Neo-adjuvant treatment in patients with pancreatic cancer with nab-paclitaxel and gemcitabine
    Pomillo, A.
    Santoro, M.
    Iuliano, E.
    Luci, M.
    Perricelli, A.
    Iuliano, F.
    Mazzulla, M. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy
    Nishioka, Mariko
    Okano, Naohiro
    Wakabayashi, Masashi
    Ikeno, Takashi
    Hayashi, Masato
    Mizutani, Tomonori
    Nagashima, Fumio
    Furuse, Junji
    ANTICANCER RESEARCH, 2024, 44 (03) : 1233 - 1239
  • [44] Trametinib, a MEK inhibitor, augments nab-paclitaxel based chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Monahan, Sheena
    Stefaniak, Alexis
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER RESEARCH, 2017, 77
  • [45] Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
    Camblin, Adam J.
    Pace, Emily A.
    Adams, Sharlene
    Curley, Michael D.
    Rimkunas, Victoria
    Nie, Lin
    Tan, Gege
    Bloom, Troy
    Ladevaia, Sergio
    Baum, Jason
    Minx, Charlene
    Czibere, Akos
    Louis, Chrystal U.
    Drummond, Daryl C.
    Nielsen, Ulrik B.
    Schoeberl, Birgit
    Pipas, J. Marc
    Straubinger, Robert M.
    Askoxylakis, Vasileios
    Lugovskoy, Alexey A.
    CLINICAL CANCER RESEARCH, 2018, 24 (12) : 2873 - 2885
  • [46] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [47] Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC).
    Ernani, Vinicius
    Akunyili, Ikechukwu Immanuel
    Hosein, Peter Joel
    Macintyre, Jessica
    Lima, Caio Max S. Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [48] Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Kronenberger, David
    Stefaniak, Alexis
    Hassan, Md Sazzad
    von Holzen, Urs
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER LETTERS, 2019, 459 : 41 - 49
  • [49] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
12345